HVB MINI FUTURE BEAR - ASTRAZENECA | Market Closed - BOERSE MUENCHEN 01:15:46 18/05/2024 am IST | ||
| 1.46 EUR | +3.55% |
|
| Current month | -5.19% | ||
| 1 month | -47.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.46 | +3.55% |
| 16/24/16 | 1.41 | +3.68% |
| 15/24/15 | 1.36 | +7.94% |
| 14/24/14 | 1.26 | +2.44% |
| 13/24/13 | 1.23 | +6.96% |
Real-time BOERSE MUENCHEN
Last update May 18, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HB8CKJ |
| ISIN | DE000HB8CKJ8 |
| Date issued | 11/07/2022 |
| Strike | 13,324 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.36 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.72 € |
|---|---|
| Lowest since issue | 1.07 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Certificates
- Certificat
